Inhibrx Highlights Progress and Financial Results for Q2 2025
Inhibrx Reports Strong Q2 2025 Financial Overview
Inhibrx Biosciences, Inc. (NASDAQ: INBX) recently revealed its financial results for the second quarter of 2025, showcasing the company’s ongoing growth trajectory and clinical advancements. Following the successful sale of INBRX-101 to Sanofi S.A., Inhibrx has streamlined to focus on two key programs currently in clinical trials, with data expected to be shared soon. The transition from being a subsidiary has allowed the company to refine its strategy and foster innovative approaches in its therapeutic development.
Exciting Clinical Milestones on the Horizon
Progress in Ongoing Trials
The Phase 2 trial for ozekibart (INBRX-109), aimed at treating unresectable or metastatic conventional chondrosarcoma, has reached full enrollment as of July 2025. The trial will require the completion of 151 progression-free survival events before the results can be disclosed. Inhibrx anticipates unveiling these results by late October 2025, along with interim data from expansion cohorts focused on Ewing sarcoma and colorectal cancer.
Future Data Releases
Inhibrx also expects to release initial Phase 2 data from the INBRX-106 trial, which studies head and neck squamous cell carcinoma in conjunction with the immunotherapy KEYTRUDA (pembrolizumab), during the fourth quarter of 2025. Additionally, interim data from a checkpoint inhibitor refractory trial in non-small cell lung cancer is anticipated to be available by the same timeframe.
Financial Results Highlight Growth
Cash Position and Revenue Growth
As of June 30, 2025, Inhibrx reported cash and cash equivalents totaling $186.6 million, a decrease from $216.5 million at the end of March 2025. The company achieved revenue of $1.3 million in Q2 2025, markedly up from just $0.1 million during the same quarter in 2024. The revenue increase was largely attributed to the fulfillment of performance obligations under a licensing agreement with Scithera, Inc.
Operational Expenses and Net Income
Research and development expenses totaled $22.3 million for the second quarter, substantially less than the $67.6 million reported in the prior year. This significant reduction is a result of the absence of one-time expenses associated with the INBRX-101 program and other non-recurring costs from 2024. General and administrative expenses also dropped to $6.4 million from $93.4 million due to elimination of historical costs linked to the prior company structure.
Despite these positive indicators, the net loss for Q2 2025 was $28.7 million, translating to $1.85 per share. This compares to a substantial net income of $1.9 billion in the same period last year, which had been inflated by a gain related to the 101 transaction.
About Inhibrx Biosciences, Inc.
Inhibrx stands as a pioneering clinical-stage biopharmaceutical entity with a focus on developing innovative biologic therapeutics. The company's investment in diverse protein engineering methodologies illustrates its commitment to meet the intricate demands of disease biology. Founded in January 2024 as a key player following its restructuring, Inhibrx has carved a niche for itself with a strong clinical pipeline, emphasizing ozekibart and INBRX-106, both designed for precise targeting and efficacy.
Frequently Asked Questions
What are the key highlights from Inhibrx's Q2 2025 financial results?
Inhibrx reported revenue growth to $1.3 million, with a cash position of $186.6 million. However, the company also recorded a net loss of $28.7 million.
What ongoing clinical trials is Inhibrx involved in?
Inhibrx is conducting clinical trials for ozekibart (INBRX-109) and INBRX-106, with significant data expected in late 2025.
How did operational expenses change for Inhibrx?
The company saw its research and development expenses drop significantly to $22.3 million in Q2 2025, down from $67.6 million in Q2 2024.
What strategic steps has Inhibrx taken after the recent sale of INBRX-101?
Inhibrx has focused on refining its clinical pipeline and enhancing operational efficiency following the successful sale and spin-off.
Where can I find more information about Inhibrx?
More information about Inhibrx and its therapeutic candidates can be found on their official website.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.